Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seizures and arterial hypertension in a child: A case of post-streptococcal glomerulonephritis evolving into posterior reversible encephalopathy syndrome.

Neurology perspectives·2026
Same author

Isolated bilateral facial palsy as the initial presenting manifestation of generalized myasthenia gravis preceding myasthenic crisis.

Neurologia·2026
Same author

Alcoholic Wernicke's encephalopathy with cranial neuropathies, atypical neuroimaging, dry beriberi, and Graves' disease: A novel variant?

Neurologia·2026
Same author

HbE/β-thalassemia presenting with Moyamoya angiopathy-associated ischemic stroke and noncompressive intrathoracic extramedullary hematopoiesis.

Neurology perspectives·2026
Same author

Wernicke's encephalopathy in a non-alcoholic woman from rural India: A rare neurological complication of acute pancreatitis.

Neurology perspectives·2025
Same author

Cockayne syndrome B with axonal sensorimotor polyneuropathy caused by a de novo mutation of the gene ERCC6: A novel phenotypic and genotypic variant.

Neurologia·2025

Related Experiment Videos

Antiinflammatory activity of a polyherbal formulation.

S R Deorukhakar1, A Dethe, R R Vohra

  • 1Department of Pharmacology, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai-400 614, India.

Indian Journal of Pharmaceutical Sciences
|March 4, 2011
PubMed
Summary

The polyherbal formulation Entox demonstrated significant anti-inflammatory effects in rat models. Its activity in reducing inflammation was comparable to the standard drug indomethacin.

Keywords:
Entox®antiinflammatorycarrageenancotton pellet granulomaformulationpolyherbal

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Natural Product Research
  • Inflammation Studies

Background:

  • Inflammation is a complex biological response implicated in various diseases.
  • Natural products are increasingly explored for therapeutic anti-inflammatory properties.
  • Entox is a polyherbal formulation with potential therapeutic applications.

Purpose of the Study:

  • To investigate the anti-inflammatory activity of the polyherbal formulation Entox(®).
  • To evaluate Entox(®) in established acute and sub-acute inflammation models in rats.

Main Methods:

  • Carrageenan-induced rat paw edema model for acute inflammation.
  • Cotton pellet granuloma method for sub-acute inflammation.
  • Oral administration of Entox(®) at doses of 300 mg/kg and 600 mg/kg.

Main Results:

  • Entox(®) significantly inhibited carrageenan-induced paw edema by 51.61% (300 mg/kg) and 54.84% (600 mg/kg) at 3 hours.
  • The formulation reduced cotton pellet granuloma by 27.92% (300 mg/kg) and 53.17% (600 mg/kg).
  • Anti-inflammatory activity was comparable to the standard drug, indomethacin.

Conclusions:

  • Entox(®) exhibits significant anti-inflammatory activity in both acute and sub-acute experimental models.
  • The findings support the potential of Entox(®) as a therapeutic agent for inflammatory conditions.
  • Further research into the specific active compounds and mechanisms of Entox(®) is warranted.